SEC Form 4 · accession 0001127602-17-003200
AMGEN INC · AMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean E Harper
Officer — EVP, Research & Development
Period of report
Jan 28, 2017
Accepted (ET)
Jan 31, 2017 · 7:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000318154
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 28, 2017 | F | 1,056 | $157.16 | D | 45,955 | D | |
| Common StockF1,F2 | Jan 30, 2017 | F | 513 | $157.16 | D | 45,442 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares include the following RSUs granted under the Company's equity plans: 3,380 RSUs which vest in two installments of 1,665 and 1,715 on 1/31/2017 and 1/31/2018, respectively; 2,640 RSUs which vest in two installments of 1,300 and 1,340 on 1/30/2018 and 1/30/2019, respectively; and 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- F2These shares include 438 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.